Non-Small Cell Lung Cancer (NSCLC): Types, Symptoms, Stages, Diagnosis and Treatment (2026 Guide)

Medically reviewed content · Published 2026 · Last reviewed August 2026

Non-small cell lung cancer (NSCLC) is a group of lung cancers that together account for about 85% of all lung cancer cases. The main histologic types are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, though modern pathology recognizes additional subtypes. NSCLC is not one disease — treatment depends heavily on the exact histologic subtype, the cancer’s stage, and, increasingly, specific molecular alterations (like EGFR mutations or ALK rearrangements) that some tumors carry and others don’t. NSCLC is biologically and clinically distinct from small cell lung cancer (SCLC), which behaves and is treated differently.

This guide explains the main types of NSCLC, how it’s diagnosed and staged, the molecular testing that increasingly drives treatment decisions, current treatment options by stage including surgery, radiation, chemotherapy, immunotherapy, and biomarker-matched targeted therapy and what NSCLC treatment and its cost look like for international patients considering care in India. This is general medical education, not a diagnosis or an individual treatment recommendation.

NSCLC vs. Small Cell Lung Cancer

SCLC is a biologically and therapeutically distinct disease from NSCLC, not simply a “more severe” version of it — the two require different diagnostic workups and different treatment strategies, and this guide focuses specifically on NSCLC.

Types of Non-Small Cell Lung Cancer

Adenocarcinoma

The most common NSCLC subtype today. It often arises in the peripheral (outer) regions of the lung and can occur in people who have never smoked — it’s the NSCLC subtype most associated with never-smokers, though it certainly also occurs in smokers. Adenocarcinoma is more commonly associated with actionable molecular alterations (such as EGFR mutations) than some other NSCLC subtypes, which is why molecular testing is particularly emphasized for this histology.

Squamous cell carcinoma

Often arises more centrally in the lung, near the larger airways, though it can occur elsewhere. It has a strong association with tobacco exposure and can cause airway-related symptoms like coughing up blood or recurrent infections due to airway obstruction. Not every squamous tumor is centrally located, and molecular-targeted therapy plays a smaller role in this subtype than in adenocarcinoma, though immunotherapy is still highly relevant.

Large cell carcinoma

A category that has become much less common under modern pathology classification many tumors once labeled “large cell carcinoma” are now more precisely reclassified using immunohistochemistry into other categories (such as poorly differentiated adenocarcinoma or squamous cell carcinoma), so the diagnosis is applied more narrowly today than it once was.

Other NSCLC histologies

Less common variants include adenosquamous carcinoma (features of both adenocarcinoma and squamous cell carcinoma) and sarcomatoid carcinoma (a more aggressive, less common variant). These and other rare subtypes are managed by the same general staging and treatment framework, with specific nuances your treating oncologist will address.

Symptoms of NSCLC

Early NSCLC frequently causes no symptoms at all and is discovered incidentally on imaging done for another reason, or through lung cancer screening in eligible high-risk individuals. When symptoms do occur, they can include:

• A persistent or worsening cough
• Coughing up blood
• Shortness of breath
• Chest pain
• Wheezing
• Recurrent respiratory infections
• Hoarseness
• Unexplained weight loss
• Fatigue
• Loss of appetite

Symptoms alone cannot diagnose NSCLC many of these overlap with common, non-cancerous respiratory conditions. Persistent or worsening symptoms, particularly in someone with risk factors, warrant medical evaluation.

Symptoms by location or spread

Some metastatic disease, particularly in the liver or adrenal glands, can remain entirely asymptomatic and is found only through staging imaging.

Paraneoplastic syndromes

Some lung cancers produce substances that cause symptoms in other parts of the body, unrelated to direct tumor spread. Examples include hypercalcemia (high blood calcium, causing fatigue, confusion, or constipation), SIADH (a hormone imbalance causing low sodium), and hypertrophic osteoarthropathy (joint pain and swelling, often with clubbing of the fingers). These are not universal most NSCLC patients don’t experience a paraneoplastic syndrome — and they are distinct from metastatic spread; they reflect substances the tumor releases, not the tumor physically being present in that location.

Causes and Risk Factors

Evidence-supported risk factors for NSCLC include:

• Cigarette smoking — the single largest risk factor
• Secondhand smoke exposure
• Radon exposure
• Occupational exposures, including certain industrial chemicals
• Asbestos exposure
• Air pollution
• Previous radiation exposure to the chest
• Family history and genetic susceptibility
• Increasing age

NSCLC does occur in people who have never smoked — this is particularly true for adenocarcinoma — and a lung cancer diagnosis is not evidence of any particular behavior or fault. Risk factors describe population-level associations, not individual causation, and many people with several risk factors never develop lung cancer, while some people with none do.

Lung Cancer Screening

For people at sufficiently high risk, annual low-dose CT (LDCT) screening is the current evidence-based approach not a routine chest X-ray, which has not been shown to reduce lung cancer mortality the way LDCT has. Current U.S. guidelines (American Cancer Society and U.S. Preventive Services Task Force-aligned criteria) generally recommend annual LDCT for adults aged 50–80 with a smoking history of at least 20 pack-years who currently smoke or quit within the past 15 years; some organizations use a slightly different age range (55–77) and pack-year threshold (30).

A “pack-year” equals smoking one pack a day for one year (or an equivalent combination, such as two packs a day for ten years). Eligibility criteria and screening infrastructure vary significantly by country — if you’re outside the U.S., check the specific guidance and availability in your own healthcare system, since implementation is much more established in some countries than others. Anyone considering screening should discuss the individual benefits, limitations, and potential harms (including false positives requiring follow-up testing) with a healthcare professional first.

How NSCLC Is Diagnosed?

NSCLC diagnosis typically involves:

1. Clinical assessment – Medical history, symptoms, smoking history, and physical examination.
2. Chest imaging – Chest X-ray may raise suspicion, followed by a contrast-enhanced CT scan of the chest and upper abdomen.
3. PET/CT scan – Helps determine whether cancer has spread, although inflammation or infection can sometimes appear similar to cancer.
4. Brain MRI – Used when brain metastases are suspected or as part of staging for appropriate patients.
5. Biopsy – Tissue is collected through bronchoscopy, EBUS, CT-guided biopsy, or surgery, depending on tumor location.
6. Pathology and IHC – Confirms NSCLC subtype and helps distinguish lung cancer from other cancers.
7. Molecular testing – Identifies actionable mutations such as EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK, and HER2.
8. PD-L1 testing – Helps determine whether immunotherapy may be appropriate.
9. Staging – The TNM system evaluates the primary tumor (T), lymph nodes (N), and distant spread (M).
10. Multidisciplinary planning – Specialists review the results to determine the most suitable treatment.

Molecular Testing and Biomarkers

Broad next-generation sequencing (NGS) is increasingly used, particularly in advanced non-squamous NSCLC, to identify mutations that may respond to targeted therapies.

Testing can use tumor tissue or liquid biopsy (ctDNA). Liquid biopsy is useful when tissue is insufficient or difficult to obtain, but a negative result may still require tissue testing.

PD-L1 is another important biomarker used to guide immunotherapy decisions. However, treatment choices depend on the complete picture, including stage, histology, molecular findings, and overall health.

NSCLC Staging

It is staged using the TNM system:

• Stage I: Cancer is generally confined to the lung.
• Stage II: Larger tumors and/or nearby lymph-node involvement may be present.
• Stage III: Locally advanced disease involving regional structures or lymph nodes.
• Stage IV: Cancer has spread to distant organs such as the brain, bones, liver, or adrenal glands.

NSCLC Treatment

Treatment depends on stage, tumor subtype, biomarkers, and overall health. Options include:

• Surgery: Lobectomy, segmentectomy, wedge resection, or pneumonectomy.
• Radiation therapy: Including SBRT for selected early-stage or metastatic tumors.
• Chemotherapy: Used before or after surgery, with radiation, or for advanced disease.
• Immunotherapy: Particularly important for patients without actionable driver mutations.
• Targeted therapy: Used when specific mutations such as EGFR, ALK, ROS1, or MET are identified.

For brain or limited metastatic disease, surgery, stereotactic radiosurgery, radiation, targeted therapy, or systemic treatment may be considered depending on the individual case.

Can NSCLC be cured?

Early-stage NSCLC can sometimes be cured, most often through surgery, with or without additional treatment depending on pathology and biomarker findings. Locally advanced (Stage III) disease may sometimes be treated with curative intent, using combinations of surgery, chemoradiation, and immunotherapy. Metastatic (Stage IV) disease is generally treated with the goal of long-term control, symptom relief, and extending survival — though it’s honest to note that selected patients, particularly those who respond exceptionally well to targeted therapy or immunotherapy, or those with genuinely limited oligometastatic disease treated aggressively, can achieve prolonged remission lasting years.

No responsible source can promise cure for metastatic disease as a general rule, but “Stage IV” and “no realistic treatment goal beyond comfort” are not the same thing for many NSCLC patients today.

Supportive and Palliative Care

Supportive care accompanies active NSCLC treatment rather than replacing it, and addresses pain, breathlessness, fatigue, nutrition, cough, anxiety, sleep difficulties, and treatment-related side effects. Palliative care specifically focuses on quality of life and symptom control and can be introduced at any point — including early, alongside curative-intent treatment — and does not mean cancer treatment has stopped.

Smoking cessation

For patients who currently smoke, stopping after an NSCLC diagnosis can improve general health, support better tolerance of treatment (including surgery and radiation), reduce complication rates, and in some cases improve eligibility for certain procedures. This is offered as practical, supportive information, not as a judgment on smoking history many NSCLC patients have never smoked, and for those who have, the diagnosis itself is not evidence of any personal failing.

Non-Small Cell Lung Cancer Treatment Cost in India

There is no single “NSCLC treatment cost” — total cost depends entirely on stage, histology, molecular findings, and which combination of treatments a specific patient needs. Below is a component breakdown based on currently published figures, which vary meaningfully by source, city, and hospital tier.

Targeted therapy can be a major part of NSCLC treatment cost in India. Older EGFR drugs may cost under $1,000/month, while newer or combination therapies can exceed $2,000–$2,500/month.

Typical overall costs may be:

• Early-stage NSCLC: $12,000–$25,000
• Locally advanced NSCLC: $15,000–$35,000
• Metastatic NSCLC: Varies widely due to ongoing targeted therapy or immunotherapy costs.

The final cost depends on the cancer stage, molecular profile, treatment protocol, drug choice, and treatment duration. International patients should request an itemized estimate based on their medical reports.

Why International Patients Consider India for NSCLC Care, and How to Choose a Center

India has developed substantial thoracic oncology infrastructure, including access to comprehensive molecular testing, PET/CT, SBRT, immunotherapy, and a broad range of targeted therapies, alongside costs generally lower than the US, UK, or much of Europe. That said, India isn’t automatically “the best” choice for every patient — several countries, including parts of Southeast Asia and Europe, also offer strong thoracic oncology programs, and the right choice depends on an individual patient’s specific disease, budget, and travel considerations.

When evaluating a center for NSCLC care in India or anywhere look for:

• A dedicated thoracic oncologist and thoracic surgeon, not general oncology coverage alone
• A pulmonologist or interventional pulmonologist for biopsy procedures like EBUS
• A radiation oncologist with SBRT capability
• A thoracic radiologist and molecular pathologist
• In-house PET/CT and comprehensive molecular testing (broad-panel NGS, not just single-gene testing) with reasonable turnaround
• Access to current-generation immunotherapy and targeted therapy agents
• ICU-level supportive care capability
• A multidisciplinary thoracic tumor board
• Clinical trial access, where relevant to your situation
• Established international patient services (visa letters, coordination, interpreter support)

Verify accreditation, named specialist credentials, and specific molecular testing turnaround directly with the hospital, rather than relying solely on third-party “top hospital” listicles, which are common in this space and don’t substitute for independent verification.

The International Patient Treatment Journey

1. Share existing imaging and medical reports for review
2. Obtain pathology review, ideally including confirmation of histologic subtype
3. Determine stage using current TNM criteria
4. Complete molecular and PD-L1 testing if not already done
5. Multidisciplinary specialist consultation
6. Determine treatment intent (curative vs. disease control) with the treating team
7. Hospital and specialist confirmation
8. Written, itemized treatment plan and cost estimate
9. Medical visa guidance
10. Travel and accommodation arrangements
11. Begin treatment
12. Monitor response and manage side effects
13. Follow-up planning
14. Remote follow-up and report-sharing with the home-country physician

No credible provider can guarantee a diagnosis, surgical eligibility, targeted-therapy eligibility, immunotherapy response, cure, an exact final cost, visa approval, or survival outcome before reviewing a patient’s actual imaging, pathology, and molecular results — be cautious of any provider offering these guarantees upfront.

How Shifam Health Helps International NSCLC Patients

Shifam Health is a medical tourism facilitator, not a cancer hospital, thoracic oncology clinic, pathology laboratory, or radiation center — we don’t diagnose NSCLC or determine treatment plans. What we do is help international patients navigate the practical side of accessing NSCLC care in India: coordinating the review of imaging and pathology by relevant specialists, helping shortlist hospitals with genuine thoracic oncology and molecular testing capability relevant to your case, obtaining written treatment and cost estimates, assisting with medical visa documentation, arranging airport pickup and accommodation, providing interpreter support where needed, and staying in touch for follow-up communication once you return home.

If you or someone you’re caring for has received an NSCLC diagnosis and you’re trying to understand what treatment in India could realistically look like, share your available reports with our team on WhatsApp or through a quick inquiry form — there’s no obligation, and we typically respond within 24 hours.

Frequently Asked Questions

People Ask Further Questions

Conclusion

Non-small cell lung cancer is a heterogeneous group of cancers, and histology, stage, and increasingly specific molecular alterations fundamentally change what treatment looks like for a given patient. A diagnosis of “NSCLC” alone tells you far less than the combination of subtype, TNM stage, PD-L1 status, and molecular testing results does. If you or someone you’re caring for has received an NSCLC diagnosis, understanding these distinctions and making sure comprehensive molecular testing has actually been done before treatment decisions are finalized — is one of the most useful steps you can take before deciding on a treatment path, in India or anywhere else.

This article is for general medical education and does not replace individualized advice from a qualified thoracic oncologist, pulmonologist, thoracic surgeon, or radiation oncologist. It is not a diagnosis, treatment recommendation, or guarantee of any outcome.